Clinical Trial AnalysisKey debates following the readout centered on TRML's use of an mITT analysis and the trial's placebo response on hs-CRP reduction, but these concerns are seen as overblown.
Market CompetitionFailure to achieve commercial success due to market size, penetration rate, and/or competition remains a risk for pacibekitug.
Regulatory And Market RisksRisks include failure of pacibekitug in clinical trials, failure to secure regulatory approval in the U.S., failure to achieve commercial success due to market size, penetration rate, and/or competition, and potential dilution risk.